Score 7.3 (out of 10): Biogen shares have -7.5% downside over next 2 months

56

Insight:

BIOGEN has reached a new shorter-term low. During similar occasions, BIOGEN shares declined -7.5%, on average, over the following 2 months based on 10 historical occasions with 8 of those showing negative returns (80% hit ratio). This sell signal for BIOGEN received a high score of 7.3 (out of 10).

Story:

BIOGEN had another setback for their controversial Alzheimer’s drug with two major hospitals saying they won’t administer Biogen’s drug to treat Alzheimer’s disease. Scientists have questioned the drug’s effectiveness and possible serious side effects while doctors have also questioned its $56,000 annual price tag.

Details:

NameBIOGEN
ViewDown
Star (1 to 10)7.3
Target-7.5%
Time2 months
Hit Rate80%

Leave a Reply